Figure - available from: Hematology
This content is subject to copyright. Terms and conditions apply.
A comparison of survival time between the MM group and the DM-MM group, MM group and the MM-SID group. There was no significant difference in between the MM group and the MM-SID. The difference between MM group and the DM-MM group was significant. The survival time of the MM group was significantly longer than that of the DM-MM group.
Source publication
Objective
The incidence of MM in most registries remains stable or showing only a slightly increase. However, prevalence of MM is increasing due to the increase in overall survival in the last two decades. The aim of this study was to observe changes in biochemical parameters during the diagnosis and treatment of MM.
Methods
A retrospective analys...
Similar publications
Introduction
In Madagascar, the epidemiologic, therapeutic, and evolutionary aspects of multiple myeloma remain poorly understood. Our objectives were to describe the cases, report factors associated with mortality, and estimate patient survival.
Patients and method
This was a retrospective descriptive and analytical study conducted in five teachi...
Citations
... Multiple myeloma is a malignant condition that originates in plasma cells, which are a type of white blood cell responsible for producing antibodies that disrupt bone health and bone marrow function, leading to an array of clinical presentations, such as hypercalcemia, anemia, and renal insufficiency (1). Reports suggest that diabetes mellitus is a complication in 6%-24% of multiple myeloma cases (2,3). Diabetes mellitus is a metabolic disorder characterized by high blood glucose levels that can occur due to insulin deficiency or the impaired ability of the body to use insulin (4). ...
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.
